Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.
about
Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional studyReporting bias in medical research - a narrative reviewFactors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than othersAmphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patientsNystatin prophylaxis and treatment in severely immunodepressed patientsRoutine versus selective antifungal administration for control of fungal infections in patients with cancerIndustry sponsorship and research outcomeAntifungal agents for preventing fungal infections in solid organ transplant recipientsAssociation of trial registration with the results and conclusions of published trials of new oncology drugsOutcome reporting among drug trials registered in ClinicalTrials.govPharmaceutical industry sponsorship and research outcome and quality: systematic reviewFlaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotationsAssociation between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studiesReporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentationSPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsWhy we need easy access to all data from all clinical trials and how to accomplish itAdequacy of authors' replies to criticism raised in electronic letters to the editor: cohort studyNystatin prophylaxis and treatment in severely immunodepressed patients.Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.Routine versus selective antifungal administration for control of fungal infections in patients with cancer.Early Toronto experience with new standards for industry-sponsored clinical research: a progress report.Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.Viewing systematic reviews and meta-analysis in social research through different lenses.A strategy for managing fungal infections in haematopoietic stem cell transplantation.Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors.Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology.Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.Consensus and contention regarding redundant publications in clinical research: cross-sectional survey of editors and authors.Randomized clinical trials: what gets published, and when?Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysisThe epistemic integrity of scientific research.Using randomized controlled trials to evaluate socially complex services: problems, challenges and recommendations.Better regulation of industry-sponsored clinical trials is long overdue.Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study.Health economists meet the fourth tempter: drug dependency and scientific discourse.Implications of pharmaceutical industry funding on clinical research.Promoting transparency in pharmaceutical industry-sponsored research.Comparator bias: why comparisons must address genuine uncertainties.Letter regarding Zhu et al. entitled "Assessment of the association between XRCC1 Arg399Gln polymorphism and glioma susceptibility".
P2860
Q21203737-507B7980-280C-498B-ABED-723BD0654F14Q21203744-3A1793AF-26CB-45A2-BEC3-AFA54FBD2D26Q21563421-F548ACFD-3B5C-4E39-9A68-D5BD99918492Q24193785-689544C0-6280-4E27-87B4-45756535D300Q24193801-91F95E38-851F-4BC2-A67F-71D1732C0662Q24193817-550FC740-8C13-4397-8663-47D48AAD17DEQ24202591-8D448242-8ED4-477F-BFCE-45B855788281Q24246678-6780D4F2-1A82-4DEC-8652-68DF145DE251Q24288921-E7569517-1925-4FA0-8F33-63332ED21A7CQ24289273-2D8EA659-4569-40AF-B151-7E01103773BCQ24673248-51B62D8E-AA0E-41C6-8F89-3F2758F66209Q25257632-EDAF3D5C-352C-44DD-AFA1-90C8E279736AQ28393829-09885651-4FD6-4718-88FF-ED10E361864BQ28474127-5FEBE7E8-BC34-41A9-B1E5-B53A29B6D3ACQ28710019-EACB8045-BD83-4DF8-802E-16B439273041Q28732492-2A4C0BEB-47C4-4E13-93F6-2423FFF1E59CQ28749806-93267F62-BEB8-43E5-8BC9-A1DAED6A3B90Q30868327-9547093B-04AD-4F0F-ADB9-45713DAE6DADQ30887333-9D930B49-65CC-4E40-B02D-4C8E7E866993Q33909375-C6831AA4-E28D-4D51-84E9-AD4F0937768CQ34011069-21B8A3BB-B67C-415A-9D45-F6B793CC1664Q34025773-31271FB5-EFE2-4BD9-8896-72BD446D0D76Q34206816-722BA593-CBA4-48B2-BDC5-B43C7C4A8B84Q34294925-0E79D605-44F7-4A9E-96EE-2E7705E95B2DQ34389549-2CB1B0DC-2C5E-410D-AAB4-F542F272B47EQ34555565-30F49339-88EC-4B75-9B49-64A05D2DA586Q34578579-6B216F94-169A-4C82-8068-FD027BB971C9Q35425167-68466B9C-E882-4341-8F3C-409C3484D41CQ35890916-BDE7EC0D-B3EF-4959-974F-6C5D56FF5CB0Q37268334-CEF159ED-28D0-4F06-AD70-79E9D2CAA597Q48374636-17B92587-E8AB-484D-A400-A40FFB3AFF86Q48638807-8B0549EF-B0F8-414E-9672-BA0B83ED37ECQ49051890-BF09D4FC-818D-4042-8036-226B769AB56AQ50035929-018B8192-9D07-4BB2-901E-88EAD248CE8EQ52927347-01316ABB-F987-43E8-9BB4-7DC7FD368ECEQ52970217-4D5FCC0A-45F7-4C68-9508-9633FCA84E76Q53091529-3BBB45AF-95DF-4E3F-8EBF-B147C1E5DA61Q53113470-8290D8EC-86F2-49E7-A3E2-E32A3855E336Q53579052-A75AD1E1-2BF6-4CE8-B1F0-1A3D1B5689CF
P2860
Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Problems in the design and rep ...... ountered during meta-analysis.
@en
Problems in the design and rep ...... ountered during meta-analysis.
@nl
type
label
Problems in the design and rep ...... ountered during meta-analysis.
@en
Problems in the design and rep ...... ountered during meta-analysis.
@nl
prefLabel
Problems in the design and rep ...... ountered during meta-analysis.
@en
Problems in the design and rep ...... ountered during meta-analysis.
@nl
P356
P1476
Problems in the design and rep ...... ountered during meta-analysis.
@en
P2093
H K Johansen
P304
P356
10.1001/JAMA.282.18.1752
P407
P577
1999-11-01T00:00:00Z